Navigation Links
Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
Date:7/3/2012

BELGRADE, Mont., July 3, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, received a letter from NYSE Regulation on July 2, 2012 advising that the Company did not comply with Sections 703 and 1009 of the NYSE MKT LLC Company Guide, which required the Company to provide the NYSE MKT LLC with ten days prior notice of the June 8, 2012 record date for its upcoming 2012 Annual Meeting of Stockholders. The Company will file a Form 8-K with the Securities and Exchange Commission related to this matter. The NYSE MKT LLC also notified the Company that according to Section 401(j) of the Company Guide it needed to issue a news release. This action will NOT result in the suspension or delisting of the Company's securities.

About Bacterin International Holdings Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.  

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

INVESTOR INQUIRIES: Hayden IR James Carbonara, Regional Vice President, 646-755-7412 james@haydenir.com  

Brett Maas, 646-536-7331 brett@haydenir.com


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
2. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
3. Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year
4. UCSB professor receives award for graphene electronics research
5. Watsons Generic Yaz(R) Receives FDA Approval
6. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
7. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
8. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
9. Intimate Bridge 2 Conception, Inc. Receives $4.3M
10. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
11. BioNeutral Group Receives $400,000 in Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... Brand, joins the nation today in celebrating National Doctors’ Day. For more than ... physicians across the nation for their delivery of care, their contributions to improving ...
(Date:3/30/2017)... Rockville, Maryland (PRWEB) , ... March 30, 2017 ... ... specializing in oncology, vaccines/immunology and general medicine, recently announced the hiring of Bruce ... John Colby into the position of Associate Vice President, Proposals & Marketing. , ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... four posters at the American Association for Cancer Research (AACR) Annual Meeting ... of Vortex’s technology to rapidly collect highly enriched populations of CTCs, undamaged by ...
(Date:3/30/2017)... ... 30, 2017 , ... DrugDev will join Boston’s ... NewCo festival on April 5. NewCo invites participants to the offices of inspiring ... , DrugDev – operating at the intersection of innovative healthcare and cutting-edge technology ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):